title: Differences in the epigenetic regulation of MT-3 gene expression between parental and Cd+2 or As+3 transformed human urothelial cells.
abstract: BACKGROUND
  Studies have shown that metallothionein 3 (MT-3) is not expressed in normal urothelium or in the UROtsa cell line, but is expressed in urothelial cancer and in tumors generated from the UROtsa cells that have been transformed by cadmium (Cd+2) or arsenite (As+3).The present study had two major goals. One, to determine if epigenetic modifications control urothelial MT-3 gene expression and if regulation is altered by malignant transformation by Cd+2 or As+3. Two, to determine if MT-3 expression might translate clinically as a biomarker for malignant urothelial cells released into the urine.
  
  
  RESULTS
  The histone deacetylase inhibitor MS-275 induced MT-3 mRNA expression in both parental UROtsa cells and their transformed counterparts. The demethylating agent, 5-Aza-2'-deoxycytidine (5-AZC) had no effect on MT-3 mRNA expression. ChIP analysis showed that metal-responsive transformation factor-1 (MTF-1) binding to metal response elements (MRE) elements of the MT-3 promoter was restricted in parental UROtsa cells, but MTF-1 binding to the MREs was unrestricted in the transformed cell lines. Histone modifications at acetyl H4, trimethyl H3K4, trimethyl H3K27, and trimethyl H3K9 were compared between the parental and transformed cell lines in the presence and absence of MS-275. The pattern of histone modifications suggested that the MT-3 promoter in the Cd+2 and As+3 transformed cells has gained bivalent chromatin structure, having elements of being "transcriptionally repressed" and "transcription ready", when compared to parental cells. An analysis of MT-3 staining in urinary cytologies showed that a subset of both active and non-active patients with urothelial cancer shed positive cells in their urine, but that control patients only rarely shed MT-3 positive cells.
  
  
  CONCLUSIONS
  The MT-3 gene is silenced in non-transformed urothelial cells by a mechanism involving histone modification of the MT-3 promoter. In contrast, transformation of the urothelial cells with either Cd+2 or As+3 modified the chromatin of the MT-3 promoter to a bivalent state of promoter readiness. Urinary cytology for MT-3 positive cells would not improve the diagnosis of urothelial cancer, but might have potential as a biomarker for tumor progression.
authors.affiliation: Department of Pathology, School of Medicine and Health Sciences, University of North Dakota, Grand Forks, ND, USA. ssomji@medicine.nodak.edu.
authors.forename: Seema
authors.initials: S
authors.lastname: Somji
authors.forename: Scott H
authors.initials: SH
authors.lastname: Garrett
authors.forename: Conrad
authors.initials: C
authors.lastname: Toni
authors.forename: Xu Dong
authors.initials: XD
authors.lastname: Zhou
authors.forename: Yun
authors.initials: Y
authors.lastname: Zheng
authors.forename: Amornpan
authors.initials: A
authors.lastname: Ajjimaporn
authors.forename: Mary Ann
authors.initials: MA
authors.lastname: Sens
authors.forename: Donald A
authors.initials: DA
authors.lastname: Sens